NWNorihiro Watanabe

Norihiro Watanabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Norihiro Watanabe has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function

    by Leonard Leong, Mansi Narula, Johannes Englisch, Cheryl Ou, Maksim Mamonkin, Norihiro Watanabe

  • Open Access

    Integrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapies

    by Mansi Narula, Johannes Englisch, Cheryl Ou, Tadahiro Honda, Ismael de la Iglesia-San Sebastian, Azlann Arnett, Feiyan Mo, Maksim Mamonkin, Norihiro Watanabe

    TCR-based cell therapies offer broad targeting of tumor antigens with high sensitivity but often low durability due to insufficient costimulation (signal 2) and cytokine (signal 3) support. To address this, we developed a dual stimulatory receptor (DSR) consisting of the 4-1BBL ectodomain fused to the thrombopoietin receptor (cMPL) endodomain. DSR engages 4-1BB that is transiently upregulated upon TCR stimulation eliciting signal 2 and simultaneously activates cMPL-driven STAT3/5 phosphorylation providing signal 3. DSR increases the expansion of T cells, preserving their effector function and an effector-associated transcriptional profile upon repeated antigen stimulation. DSR arming significantly improves in vivo antitumor activity of T cells redirected to cancer through engineered TCRs or soluble T-cell engagers in diverse xenograft tumor models by enhancing T cell expansion and persistence post-infusion. These results demonstrate broad utility and establish DSR as a modular receptor for the effective and synchronized delivery of signals 2 and 3 to support TCR-based immunotherapies.

  • Open Access

    Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function

    by Leonard Leong, Mansi Narula, Johannes Englisch, Cheryl Ou, Maksim Mamonkin, Norihiro Watanabe

    Chimeric antigen receptor (CAR)-modified Vδ2 T cells are an attractive therapeutic cell platform for cancer immunotherapy. However, their clinical efficacy is limited by short in vivo persistence due to insufficient cytokine support and high susceptibility to activation-induced cell death (AICD). Through comparison of membrane-bound (mb) cytokines, we identified mbIL-18 to support superior anti-tumor activity of CAR-Vδ2 T cells in vitro and in vivo . To reduce constitutive surface exposure of IL-18 and enable antigen-driven signal 3, we fused MyD88 - the key IL-18R signaling mediator - to an extracellular domain of Fas (Fas88). Antigen stimulation-induced FasL engagement of Fas88 triggered IL-18 signaling while simultaneously protecting Vδ2 T cells from AICD. Fas88-armed human CAR-Vδ2 T cells produced superior yet stimulation-dependent in vivo expansion and functional persistence in xenograft models of hematologic and solid malignancies. Together, these findings highlight the importance of IL-18 signaling and AICD resistance for CAR-Vδ2 T cell activity, enabling a single-transgene modification to limit inflammatory risk and facilitate clinical translation.

  • Open Access

    Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study

    by Thananya Inthanachai, Chatikorn Boonkrai, Tanapati Phakham, Trairak Pisitkun, Rattapoom Thaiwong, Vichaya Chuthaphakdikun, Nithidol Sakunrangsit, Vudhiporn Limprasutr, Thanyavi Chinsuwan, Nattiya Hirankarn, et al.

    Background B7 homolog 3 (B7-H3), an overexpressed antigen across multiple solid cancers, represents a promising target for CAR T cell therapy. This study investigated the expression of B7-H3 across various solid tumors and developed novel monoclonal antibodies (mAbs) targeting B7-H3 for CAR T cell therapy. Methods Expression of B7-H3 across various solid tumors was evaluated using RNA-seq data from TCGA, TARGET, and GTEx datasets and by flow cytometry staining. B7-H3-specific mAbs were developed by immunizing mice with human B7-H3, screening with ELISA, and analyzing kinetics with surface plasmon resonance. These mAbs were used to create second-generation CAR constructs, which were evaluated in vitro and in vivo for their antitumor function. Results We identified four mAb clones from immunized mice, with three demonstrating high specificity and affinity. The second-generation B7-H3 CAR T cells derived from these mAbs exhibited robust cytotoxicity against B7-H3-positive targets and successfully infiltrated and eliminated tumor spheroids in vitro. In a xenograft mouse model of glioblastoma, these CAR T cells, particularly those derived from clone A2H4, eradicated the primary tumor, and effectively controlled rechallenge tumor, resulting in prolonged survival of the xenograft mice. In vivo T cell trafficking revealed high accumulation and persistence of A2H4-derived CAR T cells at the tumor site. Conclusions Our results provide novel B7-H3-targeted CAR T cells with high efficacy, paving the way for clinical translation of solid tumor treatment.


  • Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia

    by Wingchi K. Leung, Alejandro G. Torres Chavez, Matthew French-Kim, Paul Shafer, Maksim Mamonkin, LaQuisa C. Hill, Manik Kuvalekar, Yovana Velazquez, Ayumi Watanabe, Norihiro Watanabe, et al.

    For patients with high-risk or relapsed/refractory acute myeloid leukemia (AML), allogeneic stem cell transplantation (allo-HSCT) and the graft-versus-leukemia effect mediated by donor T cells, offer the best chance of long-term remission. However, the concurrent transfer of alloreactive T cells can lead to graft-versus-host disease that is associated with transplant-related morbidity and mortality. Furthermore, ∼60% of patients will ultimately relapse after allo-HSCT, thus, underscoring the need for novel therapeutic strategies that are safe and effective. In this study, we explored the feasibility of immunotherapeutically targeting neoantigens, which arise from recurrent nonsynonymous mutations in AML and thus represent attractive targets because they are exclusively present on the tumor. Focusing on 14 recurrent driver mutations across 8 genes found in AML, we investigated their immunogenicity in 23 individuals with diverse HLA profiles. We demonstrate the immunogenicity of AML neoantigens, with 17 of 23 (74%) reactive donors screened mounting a response. The most immunodominant neoantigens were IDH2R140Q (n = 11 of 17 responders), IDH1R132H (n = 7 of 17), and FLT3D835Y (n = 6 of 17). In-depth studies of IDH2R140Q-specific T cells revealed the presence of reactive CD4+ and CD8+ T cells capable of recognizing distinct mutant-specific epitopes restricted to different HLA alleles. These neo–T cells could selectively recognize and kill HLA-matched AML targets endogenously expressing IDH2R140Q both in vitro and in vivo. Overall, our findings support the clinical translation of neoantigen–specific T cells to treat relapsed/refractory AML.


  • Open Access

    Human platelet lysate enhances in vivo activity of CAR-Vδ2 T cells by reducing cellular senescence and apoptosis

    by Feiyan Mo, Chiou-Tsun Tsai, Rong Zheng, Chonghui Cheng, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin, Norihiro Watanabe


  • Open Access

    Data from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

    by Sujita Sukumaran, Norihiro Watanabe, Pradip Bajgain, Kanchana Raja, Somala Mohammed, William E. Fisher, Malcolm K. Brenner, Ann M. Leen, Juan F. Vera

    The adoptive transfer of chimeric antigen receptor (CAR)–modified T cells has produced tumor responses even in patients with refractory diseases. However, the paucity of antigens that are tumor selective has resulted, on occasion, in “on-target, off-tumor” toxicities. To address this issue, we developed an approach to render T cells responsive to an expression pattern present exclusively at the tumor by using a trio of novel chimeric receptors. Using pancreatic cancer as a model, we demonstrate how T cells engineered with receptors that recognize prostate stem cell antigen, TGFβ, and IL4, and whose endodomains recapitulate physiologic T-cell signaling by providing signals for activation, costimulation, and cytokine support, produce potent antitumor effects selectively at the tumor site. In addition, this strategy has the benefit of rendering our cells resistant to otherwise immunosuppressive cytokines (TGFβ and IL4) and can be readily extended to other inhibitory molecules present at the tumor site (e.g., PD-L1, IL10, and IL13).Significance: This proof-of-concept study demonstrates how sophisticated engineering approaches can be utilized to both enhance the antitumor efficacy and increase the safety profile of transgenic T cells by incorporating a combination of receptors that ensure that cells are active exclusively at the tumor site. Cancer Discov; 8(8); 972–87. ©2018 AACR.See related commentary by Achkova and Pule, p. 918.This article is highlighted in the In This Issue feature, p. 899

  • Open Access

    Data from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

    by Sujita Sukumaran, Norihiro Watanabe, Pradip Bajgain, Kanchana Raja, Somala Mohammed, William E. Fisher, Malcolm K. Brenner, Ann M. Leen, Juan F. Vera

    The adoptive transfer of chimeric antigen receptor (CAR)–modified T cells has produced tumor responses even in patients with refractory diseases. However, the paucity of antigens that are tumor selective has resulted, on occasion, in “on-target, off-tumor” toxicities. To address this issue, we developed an approach to render T cells responsive to an expression pattern present exclusively at the tumor by using a trio of novel chimeric receptors. Using pancreatic cancer as a model, we demonstrate how T cells engineered with receptors that recognize prostate stem cell antigen, TGFβ, and IL4, and whose endodomains recapitulate physiologic T-cell signaling by providing signals for activation, costimulation, and cytokine support, produce potent antitumor effects selectively at the tumor site. In addition, this strategy has the benefit of rendering our cells resistant to otherwise immunosuppressive cytokines (TGFβ and IL4) and can be readily extended to other inhibitory molecules present at the tumor site (e.g., PD-L1, IL10, and IL13).Significance: This proof-of-concept study demonstrates how sophisticated engineering approaches can be utilized to both enhance the antitumor efficacy and increase the safety profile of transgenic T cells by incorporating a combination of receptors that ensure that cells are active exclusively at the tumor site. Cancer Discov; 8(8); 972–87. ©2018 AACR.See related commentary by Achkova and Pule, p. 918.This article is highlighted in the In This Issue feature, p. 899

  • Open Access

    Supplementary Fig. S3 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

    by Sujita Sukumaran, Norihiro Watanabe, Pradip Bajgain, Kanchana Raja, Somala Mohammed, William E. Fisher, Malcolm K. Brenner, Ann M. Leen, Juan F. Vera

    Selective enrichment process of CAR- and CAR+ transgenic sub-populations

  • Open Access

    Supplementary Fig. S5 from Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment

    by Sujita Sukumaran, Norihiro Watanabe, Pradip Bajgain, Kanchana Raja, Somala Mohammed, William E. Fisher, Malcolm K. Brenner, Ann M. Leen, Juan F. Vera